Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer : A Pilot Study
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
PURPOSE: We aimed to compare the diagnostic performance of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in primary prostate cancer (PCa) patients.
PATIENTS AND METHODS: Thirty untreated primary PCa patients were enrolled. Each patient underwent 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT within a week. In addition to visual analysis, SUV was measured for semiquantitative comparison and correlation analysis.
RESULTS: 68 Ga-P16-093 PET/CT detected more positive tumors than 68 Ga-PSMA-617 PET/CT (67 vs 56, P = 0.002), especially for intraprostatic lesions (29 vs 24, P = 0.025) and lymph node metastases (23 vs 17, P = 0.034). Further, 68 Ga-P16-093 PET/CT exhibited significantly higher SUV max of matched tumors (18.3 ± 14.4 vs 13.9 ± 11.8, P < 0.001). Besides, the SUV max of high-risk patients (based on D'Amico classification) on 68 Ga-P16-093 PET/CT was significantly higher than that of low- and intermediate-risk PCa patients (20.9 ± 9.9 vs 8.9 ± 9.1 vs 10.1 ± 5.2, P = 0.007). The SUV max of tumor measured by 68 Ga-P16-093 PET/CT had a moderate association with biopsy Gleason score ( r = 0.462, P = 0.005) and prostate-specific antigen value ( r = 0.491, P = 0.002), and significantly correlated with PSMA expression ( r = 0.732, P < 0.001).
CONCLUSIONS: 68 Ga-P16-093 PET/CT exhibited higher tumor uptake and potentially better tumor detection capability than 68 Ga-PSMA-617 PET/CT, which suggested that 68 Ga-P16-093 may be more suitable in the diagnosis and staging of primary PCa patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Clinical nuclear medicine - 48(2023), 4 vom: 01. Apr., Seite 289-295 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Guochang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
68 Ga-P16-093 |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 24.01.2024 published: Print-Electronic ClinicalTrials.gov: NCT04796467 Citation Status MEDLINE |
|---|
| doi: |
10.1097/RLU.0000000000004566 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352381612 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352381612 | ||
| 003 | DE-627 | ||
| 005 | 20240124231854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/RLU.0000000000004566 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM352381612 | ||
| 035 | |a (NLM)36727866 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Guochang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer |b A Pilot Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04796467 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a PURPOSE: We aimed to compare the diagnostic performance of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in primary prostate cancer (PCa) patients | ||
| 520 | |a PATIENTS AND METHODS: Thirty untreated primary PCa patients were enrolled. Each patient underwent 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT within a week. In addition to visual analysis, SUV was measured for semiquantitative comparison and correlation analysis | ||
| 520 | |a RESULTS: 68 Ga-P16-093 PET/CT detected more positive tumors than 68 Ga-PSMA-617 PET/CT (67 vs 56, P = 0.002), especially for intraprostatic lesions (29 vs 24, P = 0.025) and lymph node metastases (23 vs 17, P = 0.034). Further, 68 Ga-P16-093 PET/CT exhibited significantly higher SUV max of matched tumors (18.3 ± 14.4 vs 13.9 ± 11.8, P < 0.001). Besides, the SUV max of high-risk patients (based on D'Amico classification) on 68 Ga-P16-093 PET/CT was significantly higher than that of low- and intermediate-risk PCa patients (20.9 ± 9.9 vs 8.9 ± 9.1 vs 10.1 ± 5.2, P = 0.007). The SUV max of tumor measured by 68 Ga-P16-093 PET/CT had a moderate association with biopsy Gleason score ( r = 0.462, P = 0.005) and prostate-specific antigen value ( r = 0.491, P = 0.002), and significantly correlated with PSMA expression ( r = 0.732, P < 0.001) | ||
| 520 | |a CONCLUSIONS: 68 Ga-P16-093 PET/CT exhibited higher tumor uptake and potentially better tumor detection capability than 68 Ga-PSMA-617 PET/CT, which suggested that 68 Ga-P16-093 may be more suitable in the diagnosis and staging of primary PCa patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Edetic Acid |2 NLM | |
| 650 | 7 | |a 9G34HU7RV0 |2 NLM | |
| 650 | 7 | |a Gallium Isotopes |2 NLM | |
| 650 | 7 | |a Gallium Radioisotopes |2 NLM | |
| 650 | 7 | |a Gallium-68 |2 NLM | |
| 650 | 7 | |a 98B30EPP5S |2 NLM | |
| 650 | 7 | |a Oligopeptides |2 NLM | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 650 | 7 | |a PSMA-617 |2 NLM | |
| 650 | 7 | |a 68 Ga-P16-093 |2 NLM | |
| 700 | 1 | |a Li, Linlin |e verfasserin |4 aut | |
| 700 | 1 | |a Zang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Haiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Kung, Hank F |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Zhaohui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical nuclear medicine |d 1993 |g 48(2023), 4 vom: 01. Apr., Seite 289-295 |w (DE-627)NLM000990795 |x 1536-0229 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2023 |g number:4 |g day:01 |g month:04 |g pages:289-295 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/RLU.0000000000004566 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2023 |e 4 |b 01 |c 04 |h 289-295 | ||